Scope and patent landscape for U.S. Patent 10,159,657 (ready-to-administer R-norepinephrine bitartrate, EDTA, low antioxidants, tight pH/isomerization/degradation limits)
U.S. Patent 10,159,657 claims a specific ready-to-administer norepinephrine (R-isomer) aqueous formulation defined by (i) R-isomer enrichment and storage stability limits (R to S isomerization cap; degradation cap), (ii) acidic pH window (about 3.8 to 4.2), (iii) substantially antioxidant-free composition, and (iv) chelating agent and salt content constraints, with EDTA and water and specific concentrations as dependent claim anchors. The claim set is broad on the chelator class (aminopolycarboxylic acids) but narrow in performance metrics (quantified isomerization and degradation) and in the R-enrichment requirement. Competitor risk concentrates on any commercial norepinephrine injection that: (a) lacks antioxidants, (b) uses EDTA or another aminopolycarboxylic acid in the claimed µg/mL range, and (c) is engineered to maintain R/S/isomerization and degradation within the claimed thresholds under defined storage conditions.
What does U.S. Patent 10,159,657 claim: ready-to-administer norepinephrine composition with chelator, low antioxidants, and tight R/S stability?
Claim 1 defines the composition-of-matter and stability “behavior” in storage. The patent is not limited to a delivery device; it is limited to a specific injectable solution composition with defined physico-chemical parameters and stability outcomes.
Core elements of independent claim 1 (practical claim scope)
Claim 1 requires all of the following in a ready-to-administer aqueous norepinephrine solution:
-
Chelating agent and salt in aqueous solution
- Aqueous solution comprising:
- Chelating agent: an aminopolycarboxylic acid at ≤ 100 µg/mL.
- Pharmaceutically acceptable salt: ≥ 0.7 wt%.
-
Norepinephrine concentration and stereochemistry
- Norepinephrine bitartrate dissolved at 16 to 64 µg/mL.
- Norepinephrine is the R-isomer.
-
Antioxidant position
- Composition is substantially free of antioxidants.
-
pH window
- Formulated with pH 3.8 to 4.2.
-
Storage performance limits (behavioral limitations)
- After storage over at least three months:
- ≤ 10% of the R-isomer form isomerizes to the S-isomer.
- Also after that storage period:
- ≤ 5% of total norepinephrine degrades to degradation products.
These parameters combine into a formulation claim whose infringement analysis is testing- and assay-dependent: both stereochemical composition (R-to-S) and degradation product quantification must fall within or be driven beyond the claimed thresholds.
What is the practical meaning of the “R-isomer” limitation?
Claim 1 states norepinephrine is an R-isomer and then imposes an R→S isomerization cap after storage. That makes the patent particularly directed to R-enriched norepinephrine preparations where conversion to S is constrained over time in the injection solution.
What is the practical meaning of “substantially free of antioxidants”?
This is an inhibitor/omission limitation. A formulation that includes meaningful amounts of antioxidants may fall outside the claim. The claim also pairs with the stability limits, so even antioxidants-free products must still meet the quantitative isomerization and degradation caps.
Which chelators and salts are covered: aminopolycarboxylic acids up to 100 µg/mL and ≥0.7 wt% salt?
Chelator scope in claim 1 vs. dependent claims
- Claim 1: “aminopolycarboxylic acid” at ≤ 100 µg/mL.
- This is a class claim. It is broad enough to include EDTA and other aminopolycarboxylic acids (e.g., related polyaminocarboxylates) so long as they meet the amount limit and the formulation performance metrics.
- Dependent claim 6: specifies EDTA.
- Dependent claim 7: chelator concentration 10 to 100 µg/mL.
- Dependent claim 8: chelator concentration 10 µg/mL.
Salt scope in claim 1
- Claim 1: pharmaceutically acceptable salt at ≥ 0.7 wt%.
- Dependent claims in your excerpt specify 0.9 wt% (claims 10-11), which is a narrower pocket within the broader minimum.
Scope implication: A competitor using a different chelator class or operating above 100 µg/mL may avoid claim 1 unless other claims capture them. A competitor using the same chelator but using less than 0.7 wt% of the salt also avoids claim 1.
How narrow is the norepinephrine concentration and pH window: 16–64 µg/mL and pH 3.8–4.2?
Norepinephrine concentration
- Claim 1: norepinephrine bitartrate 16 to 64 µg/mL.
- Dependent claims lock in specific points:
- 16 µg/mL, 32 µg/mL, 64 µg/mL (claims 12-14).
pH window with dependent granularity
- Claim 1: pH 3.8 to 4.2.
- Dependent claims refine:
- 3.8–4.1 (claim 2)
- 3.9–4.2 (claim 3)
- pH 4.0 (claim 4)
Scope implication: Even if a formulation matches chelator and antioxidants position, a pH outside 3.8–4.2 is a clean design-around. Conversely, a formulation tuned into any sub-window may still land in dependent claims.
What storage stability metrics control infringement: R→S isomerization ≤10% and degradation ≤5% after ≥3 months?
The claim’s novelty is in the coupling of formulation constraints with quantified storage outcomes.
Key stability constraints in claim 1
- After at least three months storage:
- ≤ 10% of the R-isomer isomerizes to S.
- ≤ 5% of total norepinephrine degrades to degradation products.
Dependent claim specificity on isomerization and storage conditions
- Claim 15: storage at 40°C and 75% (±5%) relative humidity.
- Claim 16: isomerization cap tightened to ≤ 6%.
- Claim 18: degradation cap tightened to ≤ 3.5%.
Scope implication: If a competitor targets “better than” the limits, it still infringes because the claims read on compositions that satisfy the caps. If a competitor targets “slightly worse than” these thresholds (for example, allowing R→S to exceed 10% under the relevant storage time), it may avoid the claim, but that also increases likelihood of product quality nonconformance or labeling shelf-life risk.
How does “dissolved oxygen ≤1 ppm” expand claim coverage: is it an independent element or dependent formulation feature?
Your excerpt includes:
- Claim 19: dissolved oxygen concentration ≤ 1 ppm.
This adds an oxygen-handling limitation that typically requires controlled packaging, headspace control, processing controls, and/or formulation handling. If Claim 19 is dependent from claim 1, it limits a subset of the compositions that also meet oxygen constraints.
Scope implication: Even if the broader Claim 1 is met without an explicit oxygen limit, Claim 19 is relevant for competitors whose solutions have higher dissolved oxygen but are otherwise tuned on pH/chelators and stability.
How strong is the patent estate position for competitors: where are the likely overlap zones?
High-overlap formulations (infringement risk zones)
A candidate infringer is most likely within the claim if it has all of the following:
- Norepinephrine bitartrate in the 16–64 µg/mL range.
- Acidic pH in 3.8–4.2.
- R-isomer as the active stereochemical state, with storage stability measured as R→S conversion ≤10% and degradation ≤5% after ≥3 months.
- Chelator is an aminopolycarboxylic acid at ≤100 µg/mL with ≥0.7 wt% pharmaceutically acceptable salt.
- Substantially antioxidant-free formulation.
In practice, this means the patent is strongest against R-stereochemical norepinephrine injection solutions engineered for stability in the absence of typical antioxidant protection.
“Design around” levers implied by claim structure
- Move pH outside the 3.8–4.2 window.
- Move norepinephrine concentration outside 16–64 µg/mL.
- Replace the chelator or raise above 100 µg/mL (or use no aminopolycarboxylic acid).
- Use a salt amount below 0.7 wt%.
- Include antioxidants in a manner not consistent with “substantially free” (but note this may also affect the stability metrics).
- Engineer stability such that after the claimed storage period, R→S conversion exceeds 10% or degradation exceeds 5% (risky commercially and regulatorily).
What patents likely cover similar subject matter around 10,159,657: formulation, stereochemistry, chelation, and stability
You provided claim text for 10,159,657, but not the patent’s bibliographic data (assignee, filing date, priority, publication number, specification examples) or the rest of the US patent family. Without that, a complete, accurate landscape that enumerates citing/published alternatives across the US would require external patent-record retrieval and cannot be produced reliably from the claim excerpt alone.
Accordingly, the analysis below focuses only on what can be derived from the claim structure and typical formulation/IP clusters.
Likely adjacent invention clusters (relevance map)
Even without enumerating specific patent numbers, this claim sits at the intersection of four common IP themes:
-
Stereochemically defined norepinephrine injections
- R-isomer preference and stability against racemization.
-
Antioxidant suppression and oxidative stability
- “substantially free of antioxidants” plus an explicit dissolved oxygen limit (claim 19).
-
Chelation control
- EDTA or aminopolycarboxylates as a metal-complexing control to reduce degradation pathways.
-
Acidic pH stabilization
- narrow pH ranges that minimize isomerization and degradation.
These clusters tend to generate follow-on patents (process tweaks, packaging oxygen control, alternative chelators, different salt systems) that may or may not satisfy the same performance thresholds.
What is the infringement test: composition meeting the claimed numerical boundaries and stability assay results?
In a typical composition case for formulation/stability patents:
How does claim scope compare across the dependent claim set: where are the narrowest pockets?
The tightest dependent claims in your excerpt:
- pH = 4.0 (claim 4).
- EDTA at 10 µg/mL (claims 6 and 8).
- norepinephrine concentration at 16/32/64 µg/mL (claims 12-14).
- salt at 0.9 wt% (claims 10-11).
- storage at 40°C and 75% RH (claim 15).
- isomerization cap ≤6% (claims 16-17).
- degradation cap ≤3.5% (claim 18).
- dissolved oxygen ≤1 ppm (claim 19).
Scope implication: The independent claim is broad enough to read on multiple parameter combinations as long as all constraints are satisfied. Dependent claims give the patentee multiple fall-back positions that can be useful if a product matches the main claim in some but not all measured attributes.
What commercial and regulatory scenarios are most likely to collide with this claim type?
Product form factors likely in-scope
- Aqueous norepinephrine bitartrate injection or ready-to-administer solution.
- Not a lyophilized form, not an oral dosage form.
Storage and testing relevance
Because claim 1 includes storage over at least three months plus quantitative stability readouts, it aligns with:
- real-world shelf-life stability studies,
- accelerated stability testing conditions (especially those resembling claim 15),
- stability-indicating assays for degradation products and chiral analysis for R/S.
What generic entry risks exist for norepinephrine products matching these constraints?
For a generic manufacturer, risk is highest when:
- the proposed generic must match an R-enriched norepinephrine active state and
- stability targets are achieved via formulation design that effectively uses:
- EDTA/aminopolycarboxylate levels ≤100 µg/mL,
- salt ≥0.7 wt%,
- pH 3.8–4.2,
- minimal antioxidants,
- and storage performance within the caps.
Because the claim is composition-plus-performance, a generic that meets specification might still infringe if those measured outcomes match the patent’s claimed thresholds.
Key Takeaways
- U.S. Patent 10,159,657 is a formulation/stability patent for ready-to-administer norepinephrine bitartrate with R-isomer stereochemistry, acidic pH (3.8–4.2), substantially antioxidant-free formulation, and defined chelator/salt levels.
- Claim 1 is broad on chelator class (aminopolycarboxylic acids ≤100 µg/mL) but narrow on numerical performance limits: after ≥3 months storage, R→S isomerization ≤10% and total degradation ≤5%.
- Dependent claims create narrower “checkpoints” (pH = 4.0, EDTA at 10 µg/mL, salt 0.9 wt%, specific drug concentrations, storage at 40°C/75% RH, tighter stability caps, dissolved oxygen ≤1 ppm).
- Competitor/design-around opportunities implied by the claim are mainly through pH, chelators/salt concentration, antioxidant content, and engineering stability outcomes beyond the claimed thresholds (commercially and regulatorily risky).
FAQs
-
If a product meets the chemical composition limits but fails the chiral stability limit, does it avoid claim 1?
The claim requires both composition parameters and the storage performance limits (R→S conversion and degradation caps). Failing the stability thresholds avoids the claim as written.
-
Does using EDTA automatically infringe the patent?
No. EDTA must also be within the claimed µg/mL amount, and the formulation must meet the additional requirements on pH, antioxidants, salt, and stored stability outcomes.
-
Can a formulation with antioxidants be outside “substantially free of antioxidants” and still meet other numeric stability limits?
The claim ties infringement to being “substantially free of antioxidants.” If antioxidants are present at levels that do not satisfy that limitation, the formulation would avoid claim 1 even if other numeric limits are met.
-
How does dissolved oxygen concentration factor into infringement?
Dissolved oxygen ≤1 ppm appears in claim 19. If claim 19 is asserted, meeting that limit becomes necessary in addition to all other dependent-chain limitations.
-
What is the most direct numerical design-around based on the claim text?
Moving pH outside 3.8–4.2 is a clear design lever, followed by moving norepinephrine concentration outside 16–64 µg/mL, changing chelator amount beyond ≤100 µg/mL, or using salt <0.7 wt%.
References
- U.S. Patent 10,159,657. (Claims provided in prompt).
